Through the Looking-Glass: Reevaluating DHEA Metabolism Through HSD3B1 Genetics

被引:21
作者
Naelitz, Bryan D. [1 ]
Sharifi, Nima [1 ,2 ,3 ,4 ]
机构
[1] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44195 USA
[2] Cleveland Clin, Genitourinary Malignancies Res Ctr, Lerner Res Inst, Cleveland, OH 44195 USA
[3] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44195 USA
[4] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA
关键词
ANDROGEN-DEPRIVATION THERAPY; CONGENITAL ADRENAL-HYPERPLASIA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; 3-BETA-HYDROXYSTEROID DEHYDROGENASE; MOLECULAR-BIOLOGY; PROSTATE-CANCER; DEHYDROEPIANDROSTERONE REPLACEMENT; SEXUAL FUNCTION; BIOSYNTHESIS; WOMEN;
D O I
10.1016/j.tem.2020.05.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Dehydroepiandrosterone (DHEA) and DHEA sulfate together are abundant adre-nal steroids whose physiological effects are mediated through their conversion to potent downstream androgens. 3 beta-Hydroxysteroid dehydrogenase isotype 1 (3 beta HSD1) facilitates the rate-limiting step of DHEA metabolism and gates the flux of substrate into the distal portion of the androgen synthesis pathway. Nota-bly, a germline, missense-encoding change, HSD3B1(1245C), results in expres-sion of 3 beta HSD1 protein that is resistant to degradation, yielding greater potent androgen production in the periphery. In contrast, HSD3B1(1245A) encodes 3 beta HSD1 protein that is easily degraded, limiting peripheral androgen synthesis. These adrenal-permissive (AP) and adrenal-restrictive (AR) alleles have recently been associated with divergent outcomes in androgen-sensitive disease states, underscoring the need to reevaluate DHEA metabolism using HSD3B1 genetics.
引用
收藏
页码:680 / 690
页数:11
相关论文
共 62 条
  • [1] Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer
    Agarwal, Neeraj
    Hahn, Andrew W.
    Gill, David M.
    Farnham, James M.
    Poole, Austin I.
    Cannon-Albright, Lisa
    [J]. JAMA ONCOLOGY, 2017, 3 (06) : 856 - 857
  • [2] Clinical perspectives in congenital adrenal hyperplasia due to 3-hydroxysteroid dehydrogenase type 2 deficiency
    Al Alawi, Abdullah M.
    Nordenstrom, Anna
    Falhammar, Henrik
    [J]. ENDOCRINE, 2019, 63 (03) : 407 - 421
  • [3] Allahdadi Kyan J., 2009, Cardiovascular & Hematological Agents in Medicinal Chemistry, V7, P260
  • [4] Dehydroepiandrosterone replacement in women with adrenal insufficiency
    Arlt, W
    Callies, F
    van Vlijmen, JC
    Koehler, I
    Reincke, M
    Bidlingmaier, M
    Huebler, D
    Oettel, M
    Ernst, M
    Schulte, HM
    Allolio, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (14) : 1013 - 1020
  • [5] Hypogonadism and the risk of rheumatic autoimmune disease
    Baillargeon, Jacques
    Al Snih, Soham
    Raji, Mukaila A.
    Urban, Randall J.
    Sharma, Gulshan
    Sheffield-Moore, Melinda
    Lopez, David S.
    Baillargeon, Gwen
    Kuo, Yong-Fang
    [J]. CLINICAL RHEUMATOLOGY, 2016, 35 (12) : 2983 - 2987
  • [6] Testosterone Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation
    Cephus, Jacqueline-Yvonne
    Stier, Matthew T.
    Fuseini, Hubaida
    Yung, Jeffrey A.
    Toki, Shinji
    Bloodworth, Melissa H.
    Zhou, Weisong
    Goleniewska, Kasia
    Zhang, Jian
    Garon, Sarah L.
    Hamilton, Robert G.
    Poloshukin, Vasiliy V.
    Boyd, Kelli L.
    Peebles, R. Stokes, Jr.
    Newcomb, Dawn C.
    [J]. CELL REPORTS, 2017, 21 (09): : 2487 - 2499
  • [7] Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences
    Chang, K-H
    Ercole, C. E.
    Sharifi, N.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 111 (07) : 1249 - 1254
  • [8] A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
    Chang, Kai-Hsiung
    Li, Rui
    Kuri, Barbara
    Lotan, Yair
    Roehrborn, Claus G.
    Liu, Jiayan
    Vessella, Robert
    Nelson, Peter S.
    Kapur, Payal
    Guo, Xiaofeng
    Mirzaei, Hamid
    Auchus, Richard J.
    Sharifi, Nima
    [J]. CELL, 2013, 154 (05) : 1074 - 1084
  • [9] Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer
    Chen, William S.
    Feng, Eric L.
    Aggarwal, Rahul
    Foye, Adam
    Beer, Tomasz M.
    Alumkal, Joshi J.
    Gleave, Martin
    Chi, Kim N.
    Reiter, Robert E.
    Rettig, Matthew B.
    Evans, Christopher P.
    Small, Eric J.
    Sharifi, Nima
    Zhao, Shuang G.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (02) : 316 - 323
  • [10] Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
    Crawford, E. David
    Heidenreich, Axel
    Lawrentschuk, Nathan
    Tombal, Bertrand
    Pompeo, Antonio C. L.
    Mendoza-Valdes, Arturo
    Miller, Kurt
    Debruyne, Frans M. J.
    Klotz, Laurence
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (01) : 24 - 38